Versant Venture Capital Reports Over 1% Dilution in Stake Due to Company Offerings
TPST is trading near its 52-week low of $1.5 (6.0% above the low).
Summary
Versant Venture Capital's stake in Tempest Therapeutics has been diluted by over 1% due to the company's recent share issuances, highlighting the impact of ongoing capital raises on major institutional investors.
Key Events · Ownership and Investor Activity · TPST
-
Institutional Stake Diluted
Versant Venture Capital's aggregate beneficial ownership percentage in Tempest Therapeutics decreased by over one percent.
-
Passive Ownership Change
The reduction in stake is attributed to dilution from the company's recent sales of additional common stock, not an active disposition by Versant.
-
Context for Recent Offerings
This filing provides insight into the impact of Tempest Therapeutics' recent capital raising activities, including private placements and S-3 registrations, on its institutional shareholder base.
Analysis · TPST · Life Sciences
This Schedule 13D/A filing by Versant Venture Capital updates their beneficial ownership percentage in Tempest Therapeutics, reflecting a decrease of over one percent due to the company's recent dilutive share issuances. This passive reduction in stake provides important context regarding the impact of Tempest Therapeutics' ongoing capital raising efforts, including recent private placements and S-3 registrations, on its institutional shareholders, especially given the company's recent 'going concern' disclosure.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.4M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.